AstraCe is a turbo-action mucolytic by Astrapharm
Cough is one of the most common reasons for adults and children to request health care (1).
More than 50 diseases are known to cause cough, including acute respiratory viral infections (73-91.9%), influenza (6-15.2%), asthma (3.2-15%), laryngitis/tracheitis (3.6-9%), pneumonia (4.0-4.2%), COPD (0.5-3.3%), heart failure (0.3%), suspected malignancy (0.2- 1.8%) and others (2AstraZe is a turbo-action mucolytic by Astrapharm).
A dry (non-productive) cough usually resolves within a few days, changing to a wet cough with wet sputum (productive), but sometimes the process may be prolonged. A cough is therefore divided according to its length:
– acute – lasting up to 3 weeks;
– prolonged – lasts between 3 weeks and 3 months;
– chronic – lasting more than 3 months.
To prevent the development of complications, it is important to start an effective cough treatment in time. To this end, Astrapharm launches AstraCe, a mucolytic and expectorant with acetylcysteine, on the pharmaceutical market.
Acetylcysteine is a derivative of the amino acid cysteine, which exhibits:
– powerful mucolytic action – it breaks the disulfide bonds of acidic mucopolysaccharides of sputum, making it less viscous and promoting expectoration when coughing;
– local anti-inflammatory effect – inhibits the synthesis of inflammatory mediators;
– anti-infective action – enhances the therapeutic effect of antibiotics and destroys massive accumulations of bacteria in the lungs.
AstraCe is available in the form of 3 g sachets containing 200 mg of acetylcysteine. When used concomitantly with antibiotics, a 2-hour interval between doses should be observed.
This medicine is available without a prescription.
Astrapharm – the art of helping people!
1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056681/
2. https://bmcprimcare.biomedcentral.com/articles/10.1186/s12875-021-01501-0
Share: